Comprehensive and Reliable Total Nucleic Acid Extraction from FFPE Samples with Covaris truXTRAC® FFPE SMART Solutions
17.4.2023 22:22:00 EEST | Business Wire | Press release
Covaris, LLC, a leader in pre-analytical sample preparation technologies, proudly unveils a comprehensive, fully automatable deparaffinization and total nucleic acid extraction workflow for formalin-fixed paraffin-embedded (FFPE) samples. Covaris truXTRAC FFPE SMART Solutions are designed for use with Covaris’ high-throughput focused-ultrasonicators and include all reagents, consumables, and accessories used in the workflow that caters to a wide range of throughput requirements.
Combining truXTRAC FFPE SMART Solutions with Covaris’ class-leading Adaptive Focused Acoustics® (AFA®) technology offers laboratories working with FFPE tissues high-quality DNA and RNA recovery in a scalable, efficient workflow that can be partially or fully automated from deparaffinization through isolation and purification steps. All this can be achieved while addressing throughput requirements and providing reliable, robust, and reproducible results. Covaris truXTRAC FFPE SMART Solutions ensure extraction and purification of DNA as well as RNA, which is otherwise difficult to process from FFPE samples. Compared to traditional workflows for FFPE samples, truXTRAC FFPE SMART Solutions do not require use of any harmful organic solvents such as xylene or hexadecane. The customized accessories included in truXTRAC FFPE SMART Solutions allow each step within the workflow to be automated and are compatible with most automated liquid handlers and on-deck or deck-adjacent instruments, such as capper/decappers, centrifuges, and Covaris’ R230 or LE220 focused-ultrasonicators.
The high-throughput focused-ultrasonicators highlighted in the workflow feature Covaris’ patented AFA technology. Using active, non-contact, mechanical deparaffinization, this technology enables complete and efficient deparaffinization without the use of harsh chemicals, resulting in recovery of high-quality DNA and RNA, while maintaining data reliability and reproducibility.
“FFPE samples contain critical information about a person’s health and hence are investigated in an array of application types,” said Annemarie Watson, CEO of Covaris, LLC. “Covaris’ truXTRAC FFPE SMART Solutions ensure high quality and yield of DNA and RNA while addressing a wide range of throughput requirements. These advantages enable researchers to generate confident, meaningful results that have impact in medical and scientific communities.”
About Covaris
Based in Woburn, MA, Covaris develops, manufactures, and markets instruments, consumables, and reagents used in pre-analytical sample preparation for genomic and proteomic analysis to help accelerate the pace of research and life science innovations. Using proprietary technologies including focused acoustic energy, Covaris’ tools achieve highly accurate and reproducible results with the goal of empowering customers to make new discoveries, develop new assays and improve bioanalytical results. Some of the non-contact applications include faster automated DNA fragmentation, cell lysis, accelerated binding partner mixing, bead resuspension, and compound formulation.
Additional information about Covaris, LLC is available at www.covaris.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230417005756/en/
Contact information
Media:
Kate Meola
Covaris, Inc.
+1 781-932-3959
kmeola@covaris.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development23.6.2026 14:05:00 EEST | Press release
VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, today announced four strategic leadership hires that advance its mission to accelerate novel therapy approvals in complex disease areas, including cell and gene therapy, oncology, and rare disease. Building on its 30-year foundation in biostatistics and its recent acquisition of the medical writing and regulatory submission business of Certara, Veristat is deepening its scientific expertise and expanding its operational leadership to meet growing client demand. Dr. Zhaohui Su and Dr. Gil Fine join Veristat’s Strategic Drug Development Advisory team in biostatistical leadership roles, collaborating with Scott Tarrant, who has been named Executive Vice President of the team. In addition, Clint Wolfe joins Veristat as Chief Human Resources Officer (CHRO). After spending his early career in academia working on clinical trials at Harvard University, Dr. Su took a biostatistical leaders
Bacardi Takes Full Ownership of TEELING® Irish Whiskey23.6.2026 14:00:00 EEST | Press release
Bacardi Limited has announced the completion of a transaction that makes the family-owned company the sole owner of the Teeling Whiskey Company and the TEELING® Irish whiskey brand. Founders Jack and Stephen Teeling will remain a part of the brand, shaping its future and driving growth for the long term as strategic advisors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623858211/en/ Three expressions of Teeling Irish Whiskey: Single Grain, Small Batch and Single Malt Today’s announcement follows the successful relationship the two companies have enjoyed since Bacardi acquired a minority stake in the Dublin-based whiskey company in 2017. Bacardi subsequently increased its stake to become the majority shareholder in 2022. “TEELING is the perfect fit for Bacardi,” says Mahesh Madhavan, Chief Executive Officer, Bacardi Limited. “The brand stands for quality, craftsmanship and a fearless approach to the category with fresh
Bending Spoons S.p.A. announces launch of initial public offering23.6.2026 13:15:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the launch of its initial public offering (the “IPO”) of its ordinary shares. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 are being offered by Bending Spoons and 23,572,375 are being offered by certain selling shareholders (the “Selling Shareholders”). In connection with the offering, Bending Spoons and the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and an additional 3,451,626 ordinary shares from the Selling Shareholders at the IPO price, less underwriting discounts and commissions. The IPO price is currently estimated to be between $26.00 and $28.00 per share. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint l
WSJ Intelligence Study: Uniquely Human Skills Deemed "Non-Replicable" in Automated Future23.6.2026 13:00:00 EEST | Press release
Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today revealed topline findings from a forthcoming study at Journal House during the Cannes Lions International Festival of Creativity. The study delivered a clear takeaway for global businesses: human cognition must be the absolute forefront of the modern corporate landscape. The findings show that uniquely human skills are vital, non-replicable, and increasingly valuable in an AI-embedded future, with creative empathy and critical thinking among the most distinctive workplace advantages. Surveying over 2,500 business professionals across the United States, United Kingdom, Italy, South Africa and Brazil, the joint initiative is the largest-scale research program ever conducted by WSJ Intelligence. The full survey results will be released in September in a deep-dive report on the growing value of human cognition. “At
Bitcoin Suisse Receives MiCAR License and Launches European Expansion23.6.2026 12:37:00 EEST | Press release
After more than a decade as Switzerland's crypto pioneer, the Bitcoin Suisse Group ("Bitcoin Suisse") is expanding across Europe. Its European entity, Bitcoin Suisse (Europe) AG, founded in 2018, has been granted a license as a Crypto Asset Service Provider (CASP) under MiCAR by the Liechtenstein Financial Market Authority (FMA), building on its long-standing registration under the Token and TT Service Provider Act (TVTG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622188006/en/ left: Andrej Majcen, Co-Founder and Group CEO of the Bitcoin Suisse Group; right: Roman Przibylla, CEO of Bitcoin Suisse (Europe) AG Across Europe, Bitcoin Suisse operates with a clear ambition: to be the first choice for high-net-worth individuals, corporates and institutional investors. This ambition is built on more than a decade of operational experience, proven across multiple market cycles in which the company’s business model has consis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom